Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

BACKGROUND: Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hee-Young, Park, Sojung, Kim, Dong Soon, Song, Jin Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194688/
https://www.ncbi.nlm.nih.gov/pubmed/30340638
http://dx.doi.org/10.1186/s12931-018-0907-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194688/
https://www.ncbi.nlm.nih.gov/pubmed/30340638
http://dx.doi.org/10.1186/s12931-018-0907-8

Ejemplares similares